A nurse holds China's Sinovac vaccine, a potential vaccine for the COVID-19, at the Sao Lucas Hospital of the Pontifical Catholic University of Rio Grande do Sul (PUCRS), in Porto Alegre, Brazil on Saturday. Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma. -REUTERS/Diego Vara
INDONESIA, Aug 11, Reuters: China's Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.
The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.
Limited time offer:
Just RM5 per month.
